In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action
RJ Slack, VJ Barrett, VS Morrison, RG Sturton… - … of Pharmacology and …, 2013 - ASPET
Vilanterol trifenatate (vilanterol) is a novel, long-acting β 2-adrenoceptor (β 2-AR) agonist
with 24 h activity. In this study, we describe the preclinical pharmacological profile of …
with 24 h activity. In this study, we describe the preclinical pharmacological profile of …
Long‐acting beta2‐agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid
EH Walters, PG Gibson, TJ Lasserson… - Cochrane Database …, 2007 - cochranelibrary.com
Background Asthma is a common respiratory disease among both adults and children and
short acting inhaled beta‐2 agonists are used widely for'reliever'bronchodilator therapy …
short acting inhaled beta‐2 agonists are used widely for'reliever'bronchodilator therapy …
Advances in Asthma and COPD Treatment: Combination Therapy with Inhaled Corticosteroids and Long-Acting β2-Agonists.
A Miller-Larsson, O Selroos - Current pharmaceutical design, 2006 - ingentaconnect.com
Asthma treatment guidelines advocate the use of long-acting β2-agonists (LABA) in addition
to inhaled corticosteroids (ICS) in patients whose asthma is uncontrolled by ICS alone …
to inhaled corticosteroids (ICS) in patients whose asthma is uncontrolled by ICS alone …